AQP5 and non-small cell lung carcinoma: Moreover, a significant expression level of AQP5 (35.3%, 144/408) in NSCLC and its association with worse clinical outcomes may warrant a future study to explore AQP5 as a novel therapeutic target for the management of NSCLC.